Edwards Lifesciences's Revenue in the fiscal year 2025 $ 6,067.40 millions
Edwards Lifesciences's Revenue in the fiscal year 2024 $ 5,439.00 millions
Edwards Lifesciences's Revenue in the fiscal year 2023 $ 6,004.00 millions
Edwards Lifesciences's Revenue in the fiscal year 2022 $ 5,382.40 millions
Edwards Lifesciences's Revenue in the fiscal year 2021 $ 5,232.50 millions
EW Revenue second quarter 2026 Y/Y Growth Comment
Edwards Lifesciences Corporation achieved in the second quarter 2026, above Company average Revenue increase of 13.66% year on year, to $ 1,741.00 millions.
Looking into second quarter 2026 results within Medical Equipment & Supplies industry 77 other companies have achieved higher Revenue growth. While Edwards Lifesciences Corporation' s Revenue growth of 13.66% ranks overall at the positon no. 1398 in the second quarter 2026.
EW Revenue ( Y/Y Growth %)
2026
2025
2024
2023
4th Quarter
December
-
42.48 %
-28.13 %
13.75 %
3rd Quarter
September
-
14.73 %
-8.58 %
12.24 %
2nd Quarter
June
13.66 %
10.55 %
-9.45 %
11.38 %
1st Quarter
March
16.71 %
-11.61 %
9.45 %
8.83 %
FY
-
11.55 %
-9.41 %
-
Financial Statements
Edwards Lifesciences's second quarter 2026 Revenue
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Edwards Lifesciences's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
28.1 %
-0.48 %
-100 %
(Mar 31 2025)
EW's II. Quarter Q/Q Revenue Comment
Edwards Lifesciences Corporation achieved in the II. Quarter 2026 above company average sequential Revenue increase of 5.64%, to $ 1,741.00 millions, from $1,648.00 millions in the first quarter.
Within Medical Equipment & Supplies industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Edwards Lifesciences's Revenue growth quarter on quarter, overall rank is 1109.
Edwards Lifesciences Corporation achieved in the II. Quarter 2026 above company average sequential Revenue increase of 5.64%, to $ 1,741.00 millions, from $1,648.00 millions in the first quarter.
Within Medical Equipment & Supplies industry 44 other companies have achieved higher Revenue quarter on quarter growth. While Edwards Lifesciences's Revenue growth quarter on quarter, overall rank is 1109.
Edwards Lifesciences's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 6,512.50
$ 6,303.30
$ 6,067.40
$ 5,599.10
$ 5,399.70
Y / Y Revenue Growth (TTM)
20.61 %
19.98 %
11.55 %
-4.62 %
-9.97 %
Year on Year Revenue Growth Overall
Ranking
# 3133
# 1908
# 1973
# 2113
# 1430
Seqeuential Revenue Change (TTM)
3.32 %
3.89 %
8.36 %
3.69 %
2.78 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2742
# 1703
# 1931
# 2395
# 1644
Cumulative Revenue growth Comment
Edwards Lifesciences saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 20.61% year on year, to $ 6,513 millions if the fiscal year would have ended in Jun 30 2026. Edwards Lifesciences's trailing twelve months Revenue growth was higher than company's average 17.65% and higher than 19.98% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 3.32 % from $6303.3 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at17.65%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 3.32 % increase from $6303.3 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 426 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1908 to 3133.
Edwards Lifesciences saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 20.61% year on year, to $ 6,513 millions if the fiscal year would have ended in Jun 30 2026. Edwards Lifesciences's trailing twelve months Revenue growth was higher than company's average 17.65% and higher than 19.98% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 3.32 % from $6303.3 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at17.65%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 3.32 % increase from $6303.3 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 426 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1908 to 3133.
About Edwards Lifesciences Revenue Growth Rates (EW), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
23.85%